Taï Forest ebolavirus

Taï Forest ebolavirus
Name	Taï Forest ebolavirus
Virus group	Filoviridae
Genus	Ebolavirus
Species	Taï Forest ebolavirus
Synonyms	Cote d'Ivoire ebolavirus
First isolated	1994
Natural reservoir	bats (hypothesized)
Disease	Ebolavirus disease (EVD)

Taï Forest ebolavirus is a species of Ebolavirus within the family Filoviridae first recognized following a 1994 outbreak in the Taï National Park region of Côte d'Ivoire linked to contact with a wild animal. It is one of the recognized species that cause Ebolavirus disease in humans and nonhuman primates and is notable for its limited documented human cases and implications for zoonotic spillover research. Public health, conservation, and virology communities have studied the virus alongside other filoviruses during responses by organizations such as the World Health Organization and the Centers for Disease Control and Prevention.

Taxonomy and virology

Taï Forest ebolavirus is classified as a species in the genus Ebolavirus of the family Filoviridae, related to species such as Zaire ebolavirus, Sudan ebolavirus, Bundibugyo ebolavirus, Reston ebolavirus, and Bombali ebolavirus. Virologists working at institutions like the Pasteur Institute (Paris), the Institut Pasteur de Côte d'Ivoire, the National Institutes of Health, and university laboratories have characterized its filamentous, enveloped virion morphology using electron microscopy pioneered by researchers connected to Max Delbrück-era virology labs and modern centers such as the Rockefeller University. Taxonomic decisions have been influenced by the International Committee on Taxonomy of Viruses and by sequence comparisons with reference genomes archived at databases maintained by the National Center for Biotechnology Information and the European Nucleotide Archive.

Discovery and history

The virus was identified after an outbreak affecting a chimpanzee researcher in 1994 in the Taï National Park region of Côte d'Ivoire, prompting investigations by teams from the Swiss Tropical and Public Health Institute, the Wildlife Conservation Society, the World Wildlife Fund, and the Institut Pasteur. Field primatologists affiliated with programs like the Jane Goodall Institute and researchers collaborating with the University of Liverpool and the University of Zurich assisted in sample collection from great apes and necropsies. Historical context includes contemporaneous outbreaks of other filoviruses such as the 1976 Ebola virus outbreak (Yambuku), the 2000 Ebola virus outbreak in Uganda, and the 2014–2016 West African Ebola epidemic, which collectively shaped global surveillance frameworks led by the World Health Organization and national public health agencies.

Genome and molecular biology

The genome of Taï Forest ebolavirus is a single-stranded, negative-sense RNA approximately 19 kb in length, organized with genes for NP, VP35, VP40, GP, VP30, VP24, and L as in other Ebolavirus species. Molecular characterization has employed sequencing platforms developed by companies and centers such as Illumina, the Wellcome Sanger Institute, and the Broad Institute, with comparative genomics performed against reference sequences from the GenBank repository. Studies of glycoprotein structure and entry mechanisms have referenced work on viral glycoprotein-mediated fusion, endosomal processing by cathepsins, and interactions with host factors studied in laboratories at institutions like Harvard University, University of Oxford, and the Max Planck Institute for Infection Biology.

Host range and reservoirs

Investigations into reservoirs implicated frugivorous bat species similar to those associated with other filoviruses, with field teams from the Smithsonian Institution, the Natural History Museum, London, and the University of Oxford conducting serological and viral RNA surveys. Collaborations involving the Food and Agriculture Organization, the World Organisation for Animal Health, and regional wildlife authorities examined links among chimpanzees, other nonhuman primates monitored by the Jane Goodall Institute, and presumed bat reservoirs such as species studied by the KENYA Wildlife Service and researchers at the University of Ghana. Conservationists from the Wildlife Conservation Society and virologists from the Institut Pasteur have emphasized interface risks at sites managed by programs like the International Union for Conservation of Nature.

Transmission and pathogenesis

Pathogenesis models draw on studies of filoviral infection pathways developed using nonhuman primate models at facilities like the United States Army Medical Research Institute of Infectious Diseases and the National Institutes of Health clinical research centers. Transmission is thought to occur via direct contact with infected bodily fluids, as characterized in outbreaks examined by the Centers for Disease Control and Prevention and the World Health Organization, and through zoonotic spillover events documented by multi-agency field teams including the European Centre for Disease Prevention and Control. Cellular tropism involves endothelial cells, macrophages, and dendritic cells, with immune evasion mechanisms described in work from the Scripps Research Institute and the Rockefeller University.

Clinical cases and epidemiology

Documented human infection remains extremely rare, with the principal recognized case in 1994 involving a scientist who developed illness following necropsy of an infected chimpanzee; clinical case management drew on protocols from the World Health Organization and case definitions used in the 2000 Uganda outbreak and the 2014–2016 West African Ebola epidemic. Epidemiologists from institutions including the London School of Hygiene & Tropical Medicine, the Johns Hopkins Bloomberg School of Public Health, and the Institut Pasteur have modeled risk factors for spillover, integrating data from surveillance systems maintained by national ministries of health and international partners like the Global Outbreak Alert and Response Network.

Prevention, diagnostics, and research implications

Prevention strategies align with infection control guidance from the World Health Organization, vaccine research led by consortia including partners at Merck & Co., GlaxoSmithKline, and university vaccine centers, and diagnostics developed by company and public laboratories using platforms validated at the Centers for Disease Control and Prevention and the Pasteur Institute. Molecular diagnostics leverage real-time RT-PCR assays designed with input from the Public Health Agency of Canada and academic groups at the University of California, San Francisco and Imperial College London. Ongoing research implications touch on One Health initiatives advocated by the United Nations Environment Programme and interdisciplinary projects funded by agencies such as the National Institutes of Health, the European Commission, and philanthropic organizations like the Bill & Melinda Gates Foundation.

Category:Filoviridae Category:Viruses described in 1994